A Phase 1 interventional study of MLN2480 in Melanoma, Metastatic Melanoma and Solid Tumor, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-10.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,049 studies in Melanoma with a site in United States, this one is the 316th largest by enrollment of the 1,749 interventional ones that give a count, is one of 79 that started in 2011, is one of 647 in phase 1, and was the 759th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,049 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 934 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 79 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,749 interventional studies, 156 across the 212 observational. Of the 1,481 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
800 of 2,049 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 4 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
141 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 141 to your calendar (.ics) → With an account.
Among the 2,049 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MLN2480
Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Also known as: TAK-580
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths
Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)
Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.
Time frame: Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])
Number of Participants With TEAEs Related to Physical Examination Findings
Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)
Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings
Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Eastern Cooperative Oncology Group (ECOG) Performance Score
ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(\>) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair \>50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.
Time frame: at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis
Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Overall Response Rate (ORR)
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Progression-free Survival (PFS)
PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.
Time frame: Baseline up to the date of first document PD, or death due to any cause, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)
Duration of Response (DOR)
DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.
Time frame: From the first documented response (CR or PR) up to the date of first documented PD (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580
Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 hours [h]) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580
Time frame: Escalation and Expansion Q2D Cohorts: C1D21 pre-dose (C=22 days [Escalation Q2D] and 28 days [Expansion Q2D]); Escalation QW Cohorts: C1D22 pre-dose (C= 28 days)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580
Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580
Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D22 at multiple time-points (up to168 h) post-dose (C=28 days)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580
Time frame: Q2D Cohorts: Cycle1 Days 1 and 21 up to 24 hours post-dose (Cycle1 length= 22 days); QW Cohorts: Cycle2 Days 1 and 22 up to 7 hours post-dose (Cycle 2 length= 28 days)
Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580
Time frame: Cycle 1 Days 1 and 21 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length= 22 days)
QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580
Time frame: Cycle 1 Days 1 and 22 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points
The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.
Time frame: Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])
Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points
The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.
Time frame: Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])
Participants took part in the study at 16 investigative sites in the United States and United Kingdom from 13 September 2011 to 16 October 2018.
| Milestone | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 7 | 7 | 3 | 3 | 13 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 3 | 3 | 7 | 7 | 3 | 3 | 13 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 3 | 2 | 3 | 5 | 4 | 0 | 2 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 8 | 16 | 1 | 6 | 11 | 20 | 2 | 19 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 8 | 16 | 1 | 6 | 11 | 20 | 2 | 19 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 12 | 1 | 5 | 8 | 9 | 2 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 4 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 0 | 1 | 1 | 5 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 4 | 3 | 3 | 3 | 7 | 7 | 3 | 3 | 13 | 4 | 16 | 8 | 16 | 1 | 6 | 11 | 20 | 19 | 2 |
| SAEs | 2 | 0 | 1 | 0 | 2 | 4 | 1 | 2 | 5 | 3 | 9 | 6 | 5 | 1 | 2 | 4 | 11 | 8 | 2 |
| Deaths | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.
| Participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) |
|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weight decreased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 0 |
| Weight increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 |
| Breath sounds abnormal | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| kilogram (kg) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 87.477 ± 15.7794 | 72.077 ± 8.2162 | 67.375 ± 17.3371 | 77.717 ± 4.1695 | 76.963 ± 21.9026 | 77.695 ± 14.3247 | 69.522 ± 17.6937 | 73.589 ± 13.2534 | 81.054 ± 23.6907 | 80.503 ± 15.7401 | 95.837 ± 30.2887 | 71.288 ± 8.6570 | 81.312 ± 17.4736 | 57.100 ± NA | 75.267 ± 15.3231 | 72.847 ± 23.8439 | 79.624 ± 16.6098 | 83.298 ± 16.3695 | 67.000 ± NA |
| Change at EOSV | 7.167 ± 16.0315 | -1.693 ± 1.4468 | 1.542 ± 1.1139 | -0.907 ± 1.3698 | 0.065 ± 1.4543 | -0.544 ± 3.1033 | 0.272 ± 1.6037 | -1.225 ± 4.5746 | -1.868 ± 4.8255 | -1.270 ± 0.0005 | -7.825 ± 20.1782 | -1.700 ± 6.2386 | -3.164 ± 3.7607 | — | -3.225 ± 2.9826 | 0.201 ± 3.7358 | -4.292 ± 6.5671 | -3.189 ± 3.9690 | — |
| Participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(\>) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair \>50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.
| score on a scale | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eastern Cooperative Oncology Group (ECOG) Performance Score | 1.0 ± 0.00 | 1.0 ± 1.00 | 1.7 ± 1.53 | 0.3 ± 0.58 | 1.3 ± 0.49 | 1.2 ± 0.45 | 1.0 ± 0.00 | 0.7 ± 0.58 | 1.0 ± 0.47 | 1.0 ± 0.00 | 0.7 ± 0.73 | 1.5 ± 0.58 | 0.6 ± 0.90 | — | 0.8 ± 0.41 | 1.2 ± 0.98 | 0.6 ± 0.74 | 0.7 ± 0.80 | 2.0 ± NA |
| Participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver function analyses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 5 | 0 | 3 | 3 | 5 | 2 | 2 |
| Skeletal and cardiac muscle analyses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 1 | 2 | 0 | 0 | 5 | 6 | 1 | 1 |
| Mineral and electrolyte analyses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
| Tissue enzyme analyses NEC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 2 | 1 | 0 | 1 |
| Renal function analyses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 0 |
| Platelet analyses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 |
| White blood cell analyses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 |
| Red blood cell analyses | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Pituitary analyses anterior | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Carbohydrate tolerance analyses (incl diabetes) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac function diagnostic procedures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coagulation and bleeding analyses | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Digestive enzymes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
| percentage of participants | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 33 | 50 | 17 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.
| months | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 1.4 (0.8 to NA) | 1.4 (1.0 to 1.4) | 1.4 (1.0 to 1.5) | 1.4 (1.4 to 1.4) | 1.5 (1.3 to 2.8) | 1.2 (0.9 to 32.5) | NA (NA to NA) | 9.2 (0.8 to 9.2) | 1.5 (0.7 to 1.9) | 1.9 (1.0 to NA) | 5.7 (1.9 to 14.3) | 2.4 (1.0 to 3.7) | 1.8 (1.8 to 3.2) | 0.8 (NA to NA) | 1.9 (1.8 to 2.2) | 1.8 (1.7 to 5.5) | 3.6 (1.8 to NA) | 2.3 (1.9 to 5.5) | 1.7 (1.6 to 1.8) |
DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.
| months | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | — | — | — | — | — | — | — | — | NA (NA to NA) | NA (NA to NA) | 6.0 (3.7 to NA) | NA (NA to NA) | 1.5 (NA to NA) | — | — | — | — | — | — |
| nanogram per milliliter (ng/mL) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: Pharmacokinetic Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 140.0 ± 86.61 | 393.1 ± 49.81 | 921.7 ± 332.40 | 1048.1 ± 290.91 | 1933.6 ± 717.03 | 2675.2 ± 1296.95 | 2072.8 ± 287.29 | 2934.0 ± 690.39 | 4459.3 ± 1475.08 | 6774.3 ± 1082.79 | 1606.9 ± 670.48 |
| Cycle 1 Day 21 | 301.5 ± 61.83 | 759.7 ± 138.59 | 2038.8 ± 1076.99 | 3321.5 ± 1275.83 | 3809.1 ± 466.85 | 4063.1 ± 782.33 | 4588.4 ± 700.04 | — | — | — | 3548.8 ± 1310.21 |
| Cycle 1 Day 22 | — | — | — | — | — | — | — | 3135.2 ± 485.70 | 4739.8 ± 2902.53 | 6460.2 ± 1632.31 | — |
| ng/mL | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: Pharmacokinetic Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 21 | 178.3 ± 42.92 | 265.5 ± 74.25 | 1080.0 ± 797.75 | 1720.0 ± 708.87 | 1739.7 ± 746.88 | 2135.0 ± 494.00 | 2700.0 ± 1088.94 | — | — | — | 2085.0 ± 672.26 |
| Cycle 1 Day 22 | — | — | — | — | — | — | — | 270.0 ± 108.00 | 898.7 ± 618.68 | 1216.7 ± 841.80 | — |
| hour | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: Pharmacokinetic Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 3.983 (2.00 to 4.07) | 2.150 (1.98 to 4.05) | 2.033 (2.00 to 4.00) | 3.917 (1.18 to 4.02) | 2.050 (1.00 to 23.82) | 4.033 (0.97 to 23.00) | 4.000 (1.98 to 6.02) | 4.150 (3.20 to 5.12) | 3.150 (1.00 to 7.88) | 3.100 (2.12 to 7.27) | 3.108 (0.98 to 7.58) |
| Cycle 1 Day 21 | 2.000 (2.00 to 4.00) | 3.050 (2.10 to 4.00) | 4.050 (2.00 to 6.12) | 2.000 (1.00 to 2.00) | 2.992 (1.00 to 8.00) | 2.808 (1.98 to 4.00) | 12.792 (2.13 to 23.45) | — | — | — | 2.192 (1.87 to 6.17) |
| Cycle 1 Day 22 | — | — | — | — | — | — | — | 3.150 (2.80 to 3.17) | 3.033 (2.10 to 23.80) | 3.950 (2.87 to 7.32) | — |
| hour | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: Pharmacokinetic Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 22 | — | — | — | — | — | — | — | 50.22 (46.4 to 59.3) | 59.06 (31.1 to 119.2) | 69.65 (61.6 to 73.0) | — |
No measurements were reported for this outcome.
| hour*nanogram per milliliter (h*ng/mL) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | Q2D Dose Expansion Phase: Pharmacokinetic Cohort |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 4799.7 ± 2570.95 | 11019.7 ± 655.03 | 30562.8 ± 16909.20 | 36061.9 ± 8904.40 | 50946.5 ± 10597.12 | 78993.3 ± 23713.60 | 66799.2 ± 7656.58 | 53522.2 ± 17337.54 |
| Day 21 | 10679.2 ± 2571.83 | 21007.9 ± 3501.86 | 43294.2 ± 10403.72 | 99626.7 ± 29090.62 | 125540.2 ± 46299.79 | 156439.3 ± 26263.33 | 165002.1 ± 19899.97 | 127026.4 ± 38244.03 |
| h*ng/mL | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) |
|---|---|---|---|
| Day 1 | 184534.4 ± 50225.97 | 278247.9 ± 128772.92 | 431723.3 ± 106266.40 |
| Day 22 | 199210.4 ± 57957.62 | 339244.8 ± 149201.72 | 477700.2 ± 86620.19 |
The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.
| percent change | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|
| Quant H-score | 180.0 (-100 to 460) | -93.5 (-97 to 1235) | -82.0 (-96 to -43) | — | -51.0 (-97 to -5) | -15.0 (-95 to 22) | -8.0 (-8 to -8) | -71.0 (-71 to -71) |
| Semi H-score | -94.5 (-100 to -89) | -80.5 (-100 to 2207) | -70.0 (-100 to 603) | — | -24.5 (-78 to 29) | -27.0 (-100 to 0) | -12.0 (-12 to -12) | -23.0 (-23 to -23) |
The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.
| percent change | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Q2D Dose Expansion Phase: TAK-580 (BRAF+) |
|---|---|---|---|---|---|---|---|---|
| cPARP Quant H-score | — | -100.0 (-100 to -93) | 317.5 (-15 to 650) | — | -100.0 (-100 to -100) | -33.5 (-100 to 200) | — | — |
| cPARP Semi H-score | — | -96.0 (-100 to -92) | -33.0 (-33 to -33) | — | -11.0 (-11 to -11) | -48.0 (-100 to 0) | — | — |
| BIM-1 Quant H-score | 265.0 (265 to 265) | 136.0 (64 to 650) | 158.0 (90 to 625) | — | -52.5 (-65 to -40) | -23.5 (-53 to 66) | 35.5 (-29 to 100) | 960.0 (960 to 960) |
| BIM-1 Semi H-score | 723.5 (47 to 1400) | 64.5 (-84 to 2533) | 64.0 (30 to 287) | — | -41.0 (-75 to -7) | -17.0 (-49 to 28) | -3.5 (-15 to 8) | — |
Collected over TEAEs are AEs that started after the first dose of study drug and no more than 30 days after the last dose of study drug (approximately Cycle 38 Days 52 [Q2D] and 58 [QW] in Escalation Phase; Cycle 49 Day 58 in Expansion Phase). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | 2/13 (15.4%) | 5/13 (38.5%) | 12/13 (92.3%) |
| QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | 0/16 (0%) | 9/16 (56.3%) | 16/16 (100%) |
| Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | 2/8 (25%) | 6/8 (75%) | 8/8 (100%) |
| Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | 2/16 (12.5%) | 5/16 (31.3%) | 16/16 (100%) |
| Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | 0/11 (0%) | 4/11 (36.4%) | 11/11 (100%) |
| Q2D Dose Expansion Phase: Pharmacokinetic Cohort | 1/20 (5%) | 11/20 (55%) | 19/20 (95%) |
| Q2D Dose Expansion Phase: TAK-580 (BRAF+) | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | 0/19 (0%) | 8/19 (42.1%) | 19/19 (100%) |
| Event | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 1/1 | 0/6 | 0/11 | 1/20 | 1/2 | 1/19 |
| ConstipationGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 1/8 | 0/16 | 1/1 | 0/6 | 0/11 | 0/20 | 0/2 | 0/19 |
| InfectionInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 1/2 | 0/19 |
| Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 1/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 1/2 | 0/19 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 1/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 1/20 | 0/2 | 0/19 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 1/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 0/2 | 0/19 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 1/3 | 0/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 0/2 | 0/19 |
| Haemorrhage intracranialNervous system disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 1/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 0/2 | 0/19 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/7 | 1/7 | 0/3 | 0/3 | 0/13 | 0/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 0/20 | 0/2 | 0/19 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 1/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 0/11 | 1/20 | 0/2 | 0/19 |
| Event | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/4 | 1/3 | 0/3 | 3/3 | 3/7 | 2/7 | 0/3 | 0/3 | 4/13 | 0/4 | 12/16 | 7/8 | 9/16 | 0/1 | 3/6 | 1/11 | 6/20 | 0/2 | 4/19 |
| NauseaGastrointestinal disorders | 0/4 | 0/3 | 1/3 | 1/3 | 2/7 | 1/7 | 0/3 | 1/3 | 5/13 | 1/4 | 5/16 | 1/8 | 5/16 | 0/1 | 1/6 | 1/11 | 11/20 | 2/2 | 5/19 |
| VomitingGastrointestinal disorders | 1/4 | 0/3 | 0/3 | 1/3 | 0/7 | 1/7 | 0/3 | 1/3 | 2/13 | 2/4 | 0/16 | 0/8 | 2/16 | 1/1 | 2/6 | 3/11 | 4/20 | 1/2 | 3/19 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 1/3 | 1/3 | 1/7 | 0/7 | 0/3 | 1/3 | 2/13 | 2/4 | 2/16 | 1/8 | 1/16 | 1/1 | 0/6 | 1/11 | 3/20 | 0/2 | 0/19 |
| Rectal haemorrhageGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 4/13 | 4/4 | 0/16 | 0/8 | 0/16 | 0/1 | 0/6 | 1/11 | 0/20 | 0/2 | 0/19 |
| FatigueGeneral disorders | 3/4 | 1/3 | 1/3 | 2/3 | 6/7 | 6/7 | 1/3 | 3/3 | 6/13 | 2/4 | 5/16 | 3/8 | 7/16 | 0/1 | 3/6 | 3/11 | 12/20 | 1/2 | 9/19 |
| PyrexiaGeneral disorders | 0/4 | 0/3 | 0/3 | 0/3 | 1/7 | 1/7 | 0/3 | 0/3 | 2/13 | 0/4 | 7/16 | 1/8 | 1/16 | 0/1 | 1/6 | 0/11 | 2/20 | 2/2 | 3/19 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/4 | 1/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 1/13 | 1/4 | 2/16 | 2/8 | 3/16 | 1/1 | 2/6 | 3/11 | 1/20 | 0/2 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 1/7 | 0/3 | 0/3 | 2/13 | 0/4 | 3/16 | 0/8 | 1/16 | 1/1 | 1/6 | 3/11 | 3/20 | 0/2 | 1/19 |
| Aspartate aminotransferase increasedInvestigations | 0/4 | 0/3 | 0/3 | 0/3 | 0/7 | 0/7 | 0/3 | 0/3 | 0/13 | 0/4 | 2/16 | 0/8 | 4/16 | 0/1 | 1/6 | 2/11 | 5/20 | 2/2 | 0/19 |
Safety population included all participants who received at least 1 dose of study drug (TAK-580).
| Age, Continuous(years) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 71.0 ± 10.10 | 66.3 ± 8.33 | 56.7 ± 10.26 | 54.7 ± 13.65 | 58.7 ± 14.77 | 65.0 ± 4.40 | 71.0 ± 6.24 | 54.7 ± 13.58 | 57.2 ± 9.34 | 66.8 ± 7.50 | 54.6 ± 12.44 | 58.9 ± 16.39 | 68.4 ± 7.86 | 56.0 ± NA | 56.7 ± 17.24 | 67.5 ± 8.69 | 65.1 ± 14.67 | 50.5 ± 0.71 | 66.1 ± 11.13 | 62.5 ± 12.47 |
| Sex: Female, Male(Participants) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 2 | 1 | 4 | 2 | 1 | 8 | 2 | 6 | 5 | 6 | 1 | 3 | 6 | 8 | 2 | 9 | 73 |
| Male | 1 | 1 | 1 | 1 | 6 | 3 | 1 | 2 | 5 | 2 | 10 | 3 | 10 | 0 | 3 | 5 | 12 | 0 | 10 | 76 |
| Ethnicity (NIH/OMB)(Participants) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 1 | 0 | 1 | 2 | 0 | 2 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 16 |
| Not Hispanic or Latino | 1 | 1 | 1 | 1 | 3 | 2 | 3 | 1 | 9 | 3 | 14 | 7 | 16 | 1 | 6 | 11 | 17 | 2 | 18 | 117 |
| Unknown or Not Reported | 1 | 1 | 1 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 16 |
| Race (NIH/OMB)(Participants) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| White | 3 | 3 | 3 | 2 | 6 | 6 | 3 | 3 | 12 | 3 | 15 | 8 | 16 | 1 | 6 | 11 | 19 | 2 | 19 | 141 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle) | Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle) | QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive) | Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive) | Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated) | Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive | Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated | Q2D Dose Expansion Phase: Pharmacokinetic Cohort | Q2D Dose Expansion Phase: TAK-580 (BRAF+) | QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 3 | 3 | 7 | 7 | 3 | 3 | 13 | 4 | 6 | 0 | 10 | 0 | 1 | 4 | 20 | 0 | 11 | 102 |
| United Kingdom | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 8 | 6 | 1 | 5 | 7 | 0 | 2 | 8 | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment."
Ran from Sep 2011 to primary completion in Apr 2017, 66 months.
Results were first posted in Aug 2020, 3 years 3 months after primary completion.
Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 66 months is above that.
Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovorafenib
Millennium Pharmaceuticals, Inc. →